Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine

Lorenzo Mortara, Paola Orecchia, Patrizia Castellani, Laura Borsi, Barbara Carnemolla, Enrica Balza

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

L19-tumor necrosis factor alpha (L19mTNF-α; L), a fusion protein consisting of mouse TNFα and the human antibody fragment L19 directed to the extra domain-B (ED-B) of fibronectin, is able to selectively target tumor vasculature and to exert a long-lasting therapeutic activity in combination with melphalan (M) in syngeneic mouse tumor models. We have studied the antitumor activity of single L19mTNF-α treatment in combination with melphalan and gemcitabine (G) using different administration protocols in two histologically different murine tumor models: WEHI-164 fibrosarcoma and K7M2 osteosarcoma. All responding mice showed significant reduction in myeloid-derived suppressor cells (MDSCs) and an increase in CD4+ and CD8+ T cells in the tumor infiltrates, as well as significant reduction in regulatory T cells (Treg) at the level of draining lymph nodes. What is important is that all cured mice rejected tumor challenge up to 1 year after therapy. Targeted delivery of L19mTNF-α synergistically increases the antitumor activity of melphalan and gemcitabine, but optimal administration schedules are required. This study provides information for designing clinical studies using L19mTNF-α in combination with chemotherapeutic drugs. Targeted delivery of L19mTNF-α synergistically increases the antitumor activity of melphalan and gemcitabine, but optimal administration schedule requires a pretreatment with L19mTNF-α otherwise an antagonistic effect could occur. This study provides information for designing clinical studies using L19mTNF-α in combination with chemotherapeutic drugs.

Original languageEnglish
Pages (from-to)478-487
Number of pages10
JournalCancer Medicine
Volume2
Issue number4
DOIs
Publication statusPublished - 2013

Fingerprint

gemcitabine
Melphalan
Appointments and Schedules
Neoplasms
Therapeutics
Immunoglobulin Fragments
Fibrosarcoma
Regulatory T-Lymphocytes
Osteosarcoma
Fibronectins
Pharmaceutical Preparations
Tumor Necrosis Factor-alpha
Lymph Nodes
T-Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine. / Mortara, Lorenzo; Orecchia, Paola; Castellani, Patrizia; Borsi, Laura; Carnemolla, Barbara; Balza, Enrica.

In: Cancer Medicine, Vol. 2, No. 4, 2013, p. 478-487.

Research output: Contribution to journalArticle

Mortara, Lorenzo ; Orecchia, Paola ; Castellani, Patrizia ; Borsi, Laura ; Carnemolla, Barbara ; Balza, Enrica. / Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine. In: Cancer Medicine. 2013 ; Vol. 2, No. 4. pp. 478-487.
@article{d4d6478df0fb426b946f119ce12bc739,
title = "Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine",
abstract = "L19-tumor necrosis factor alpha (L19mTNF-α; L), a fusion protein consisting of mouse TNFα and the human antibody fragment L19 directed to the extra domain-B (ED-B) of fibronectin, is able to selectively target tumor vasculature and to exert a long-lasting therapeutic activity in combination with melphalan (M) in syngeneic mouse tumor models. We have studied the antitumor activity of single L19mTNF-α treatment in combination with melphalan and gemcitabine (G) using different administration protocols in two histologically different murine tumor models: WEHI-164 fibrosarcoma and K7M2 osteosarcoma. All responding mice showed significant reduction in myeloid-derived suppressor cells (MDSCs) and an increase in CD4+ and CD8+ T cells in the tumor infiltrates, as well as significant reduction in regulatory T cells (Treg) at the level of draining lymph nodes. What is important is that all cured mice rejected tumor challenge up to 1 year after therapy. Targeted delivery of L19mTNF-α synergistically increases the antitumor activity of melphalan and gemcitabine, but optimal administration schedules are required. This study provides information for designing clinical studies using L19mTNF-α in combination with chemotherapeutic drugs. Targeted delivery of L19mTNF-α synergistically increases the antitumor activity of melphalan and gemcitabine, but optimal administration schedule requires a pretreatment with L19mTNF-α otherwise an antagonistic effect could occur. This study provides information for designing clinical studies using L19mTNF-α in combination with chemotherapeutic drugs.",
author = "Lorenzo Mortara and Paola Orecchia and Patrizia Castellani and Laura Borsi and Barbara Carnemolla and Enrica Balza",
year = "2013",
doi = "10.1002/cam4.89",
language = "English",
volume = "2",
pages = "478--487",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine

AU - Mortara, Lorenzo

AU - Orecchia, Paola

AU - Castellani, Patrizia

AU - Borsi, Laura

AU - Carnemolla, Barbara

AU - Balza, Enrica

PY - 2013

Y1 - 2013

N2 - L19-tumor necrosis factor alpha (L19mTNF-α; L), a fusion protein consisting of mouse TNFα and the human antibody fragment L19 directed to the extra domain-B (ED-B) of fibronectin, is able to selectively target tumor vasculature and to exert a long-lasting therapeutic activity in combination with melphalan (M) in syngeneic mouse tumor models. We have studied the antitumor activity of single L19mTNF-α treatment in combination with melphalan and gemcitabine (G) using different administration protocols in two histologically different murine tumor models: WEHI-164 fibrosarcoma and K7M2 osteosarcoma. All responding mice showed significant reduction in myeloid-derived suppressor cells (MDSCs) and an increase in CD4+ and CD8+ T cells in the tumor infiltrates, as well as significant reduction in regulatory T cells (Treg) at the level of draining lymph nodes. What is important is that all cured mice rejected tumor challenge up to 1 year after therapy. Targeted delivery of L19mTNF-α synergistically increases the antitumor activity of melphalan and gemcitabine, but optimal administration schedules are required. This study provides information for designing clinical studies using L19mTNF-α in combination with chemotherapeutic drugs. Targeted delivery of L19mTNF-α synergistically increases the antitumor activity of melphalan and gemcitabine, but optimal administration schedule requires a pretreatment with L19mTNF-α otherwise an antagonistic effect could occur. This study provides information for designing clinical studies using L19mTNF-α in combination with chemotherapeutic drugs.

AB - L19-tumor necrosis factor alpha (L19mTNF-α; L), a fusion protein consisting of mouse TNFα and the human antibody fragment L19 directed to the extra domain-B (ED-B) of fibronectin, is able to selectively target tumor vasculature and to exert a long-lasting therapeutic activity in combination with melphalan (M) in syngeneic mouse tumor models. We have studied the antitumor activity of single L19mTNF-α treatment in combination with melphalan and gemcitabine (G) using different administration protocols in two histologically different murine tumor models: WEHI-164 fibrosarcoma and K7M2 osteosarcoma. All responding mice showed significant reduction in myeloid-derived suppressor cells (MDSCs) and an increase in CD4+ and CD8+ T cells in the tumor infiltrates, as well as significant reduction in regulatory T cells (Treg) at the level of draining lymph nodes. What is important is that all cured mice rejected tumor challenge up to 1 year after therapy. Targeted delivery of L19mTNF-α synergistically increases the antitumor activity of melphalan and gemcitabine, but optimal administration schedules are required. This study provides information for designing clinical studies using L19mTNF-α in combination with chemotherapeutic drugs. Targeted delivery of L19mTNF-α synergistically increases the antitumor activity of melphalan and gemcitabine, but optimal administration schedule requires a pretreatment with L19mTNF-α otherwise an antagonistic effect could occur. This study provides information for designing clinical studies using L19mTNF-α in combination with chemotherapeutic drugs.

UR - http://www.scopus.com/inward/record.url?scp=84902081932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902081932&partnerID=8YFLogxK

U2 - 10.1002/cam4.89

DO - 10.1002/cam4.89

M3 - Article

C2 - 24156020

AN - SCOPUS:84902081932

VL - 2

SP - 478

EP - 487

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 4

ER -